---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-22-000028"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T20:01:13.229299+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics reports FY2021 net loss of $10.5M; cash $49.7M into 2024

## Summary
- Cash, equivalents and restricted cash $49.7M at Dec 31, 2021 (vs $0.3M in 2020); expected to fund operations into 2024.
- Net loss of $10.5M for FY2021 vs net income of $6.6M in 2020; R&D expenses $3.8M, G&A $3.6M.
- Closed $31.25M private placement in Dec 2021; $28.75M IPO earlier; pipeline includes three Phase 2 ONA-XR trials and CLDN6 bsAb candidate selection in 2022.
- Appointed Christopher Beck as SVP Operations and Mark Fletcher as VP R&D in Jan 2022.
- Preliminary data expected mid-2022 from first-line metastatic breast cancer and recurrent endometrial cancer trials.

## SEC filing metadata
- accession: 0001842952-22-000028
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000028/0001842952-22-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000028/cntx-20220323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-22-000028
- JSON: https://secwatch.observer/filing/0001842952-22-000028.json
- Plain text: https://secwatch.observer/filing/0001842952-22-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.